Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1994 1
1997 1
1998 1
1999 1
2001 4
2002 2
2003 2
2006 1
2007 2
2009 3
2010 6
2012 3
2013 3
2014 4
2015 5
2016 3
2018 2
2019 3
2020 2
2021 2
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Clear Cell Renal Cell Carcinoma"
Page 1
Acrometastases.
Mavrogenis AF, Mimidis G, Kokkalis ZT, Karampi ES, Karampela I, Papagelopoulos PJ, Armaganidis A. Mavrogenis AF, et al. Eur J Orthop Surg Traumatol. 2014 Apr;24(3):279-83. doi: 10.1007/s00590-013-1311-1. Epub 2013 Sep 8. Eur J Orthop Surg Traumatol. 2014. PMID: 24013815 Review.
In the foot, amputation can be that of a ray, midfoot or transtibial, depending on the location and spread of the tumor. If unresectable, palliative treatment with radiation therapy, bisphosphonates and chemotherapy is recommended. The prognosis of the patients with acrome …
In the foot, amputation can be that of a ray, midfoot or transtibial, depending on the location and spread of the tumor. If unresectable …
Treatment of advanced pediatric renal cell carcinoma.
Ambalavanan M, Geller JI. Ambalavanan M, et al. Pediatr Blood Cancer. 2019 Aug;66(8):e27766. doi: 10.1002/pbc.27766. Epub 2019 Apr 23. Pediatr Blood Cancer. 2019. PMID: 31012542
BACKGROUND: Pediatric renal cell carcinoma (pRCC) is the second most common renal malignancy of childhood; however, treatment data for advanced disease is lacking. ...Translocation morphology RCC (tRCC) was the most common subtype (16; 64%), followed b …
BACKGROUND: Pediatric renal cell carcinoma (pRCC) is the second most common renal malignancy of childhood; howev …
Renal cell carcinoma in children and adolescents.
Spreafico F, Collini P, Terenziani M, Marchianò A, Piva L. Spreafico F, et al. Expert Rev Anticancer Ther. 2010 Dec;10(12):1967-78. doi: 10.1586/era.10.188. Expert Rev Anticancer Ther. 2010. PMID: 21110762 Review.
Although rare in children and adolescents, renal cell carcinomas (RCCs) raise important questions concerning the best treatment approach and accurate pathologic classification. ...It is worth noting that the largest clinical efficacy trials on targeted molecules hav …
Although rare in children and adolescents, renal cell carcinomas (RCCs) raise important questions concerning the best treatmen …
Local and distant recurrence of the chromophobe renal cell carcinoma.
Armas-Alvarez AL, Alois Osorio-Manyari A, Donate-Moreno MJ, Vera-Beron R, Salinas-Sánchez AS. Armas-Alvarez AL, et al. Arch Esp Urol. 2020 Jan;73(1):71-75. Arch Esp Urol. 2020. PMID: 31950927 Free article. English, Spanish.
INTRODUCTION: There is still limited knowledgeabout surveillance and optimal management for patientswith recurrent chromophobe renal cell carcinoma. OBJECTIVE: Describe our experience in the diagnosis andmanagement in recurrent chromophobe renal cel …
INTRODUCTION: There is still limited knowledgeabout surveillance and optimal management for patientswith recurrent chromophobe renal …
Current management of advanced and metastatic renal cell carcinoma.
Ather MH, Masood N, Siddiqui T. Ather MH, et al. Urol J. 2010 Winter;7(1):1-9. Urol J. 2010. PMID: 20209445 Free article. Review.
INTRODUCTION: Unresectable renal cell carcinoma (RCC) is a technically incurable condition. ...
INTRODUCTION: Unresectable renal cell carcinoma (RCC) is a technically incurable condition. ...
Biopsy of renal masses: when and why.
Sahni VA, Silverman SG. Sahni VA, et al. Cancer Imaging. 2009 Jul 6;9(1):44-55. doi: 10.1102/1470-7330.2009.0005. Cancer Imaging. 2009. PMID: 19602467 Free PMC article. Review.
Percutaneous image-guided biopsy of renal masses is a safe and accurate procedure. Although once reserved for the diagnosis of unresectable renal cell carcinoma, metastases, lymphoma, and infection, today percutaneous image-guided biopsy has an …
Percutaneous image-guided biopsy of renal masses is a safe and accurate procedure. Although once reserved for the diagnosis of unr …
Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Suzuki K, et al. J Immunother. 2020 Jan;43(1):38-42. doi: 10.1097/CJI.0000000000000299. J Immunother. 2020. PMID: 31567704
The objective was to elucidate the clinical features of adrenal insufficiency related to nivolumab in patients with metastatic renal cell carcinoma (mRCC). A total of 49 consecutive patients with mRCC or unresectable renal cell carcino …
The objective was to elucidate the clinical features of adrenal insufficiency related to nivolumab in patients with metastatic renal …
Renal oncocytoma--are there sufficient grounds to consider surveillance following prenephrectomy histologic diagnosis.
Haifler M, Copel L, Sandbank J, Lang E, Raz O, Leibovici D, Lindner A, Zisman A. Haifler M, et al. Urol Oncol. 2012 Jul-Aug;30(4):362-8. doi: 10.1016/j.urolonc.2009.11.024. Epub 2010 Feb 20. Urol Oncol. 2012. PMID: 20171908 Review.
OBJECTIVES: To analyze the current status of preoperative diagnostic tools for oncocytoma, study the different occurrences of oncocytoma-renal cell carcinoma (RCC) coexistence, including the phenomenon of true hybrid tumors, and investigate the rare reports o …
OBJECTIVES: To analyze the current status of preoperative diagnostic tools for oncocytoma, study the different occurrences of oncocytoma- …
Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H. Harada K, et al. Int J Urol. 2019 Feb;26(2):202-210. doi: 10.1111/iju.13830. Epub 2018 Oct 21. Int J Urol. 2019. PMID: 30345560
OBJECTIVES: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. METHODS: A multicenter, retrospective medical chart review study was carried out. Pat …
OBJECTIVES: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carci …
Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M, Caterina I, De Divitiis C, von Arx C, Maiolino P, Tatangelo F, Cavalcanti E, Di Girolamo E, Iaffaioli RV, Scala S, Tafuto S; ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Capozzi M, et al. Int J Surg. 2015 Sep;21 Suppl 1:S89-94. doi: 10.1016/j.ijsu.2015.06.064. Epub 2015 Jun 27. Int J Surg. 2015. PMID: 26123382 Free article. Review.
Currently Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is the most promising drug for patients with unresectable, metastatic disease, in progressive well-differentiated PNETs and many studies are ongoing to demonstrate its effects on the other neuroend …
Currently Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is the most promising drug for patients with unresectable …
54 results